CEPHULAC Drug Patent Profile
✉ Email this page to a colleague
When do Cephulac patents expire, and what generic alternatives are available?
Cephulac is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in CEPHULAC is lactulose. There are twenty drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cephulac
A generic version of CEPHULAC was approved as lactulose by PHARM ASSOC on July 30th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CEPHULAC?
- What are the global sales for CEPHULAC?
- What is Average Wholesale Price for CEPHULAC?
Summary for CEPHULAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 28 |
Patent Applications: | 3,983 |
DailyMed Link: | CEPHULAC at DailyMed |
US Patents and Regulatory Information for CEPHULAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | CEPHULAC | lactulose | SOLUTION;ORAL, RECTAL | 017657-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CEPHULAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | CEPHULAC | lactulose | SOLUTION;ORAL, RECTAL | 017657-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | CEPHULAC | lactulose | SOLUTION;ORAL, RECTAL | 017657-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | CEPHULAC | lactulose | SOLUTION;ORAL, RECTAL | 017657-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | CEPHULAC | lactulose | SOLUTION;ORAL, RECTAL | 017657-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | CEPHULAC | lactulose | SOLUTION;ORAL, RECTAL | 017657-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | CEPHULAC | lactulose | SOLUTION;ORAL, RECTAL | 017657-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CEPHULAC
See the table below for patents covering CEPHULAC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
United Kingdom | 1390803 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |